Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs)

Journal of the American Academy of Dermatology

Volumn 73, Issue 3, 2015, Pages 444-450

  Asgari, Maryam M ^a,b   Arron, Sarah T ^b   Warton, E Margaret ^a   Quesenberry, Charles P ^a   Weisshaar, Dana ^c  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

immunosuppression; nonmelanoma skin cancer; pharmacoepidemiology; sirolimus; solid organ transplantation; squamous cell carcinoma

Indexed keywords

AZATHIOPRINE; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BODY MASS; CANCER RISK; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DISEASES; FEMALE; GRAFT RECIPIENT; HAZARD RATIO; HEALTH CARE UTILIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PRIMARY PREVENTION; PRIORITY JOURNAL; SKIN CARCINOMA; SUN EXPOSURE; TREATMENT DURATION; ADVERSE EFFECTS; AGED; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; INCIDENCE; PATHOPHYSIOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIROLIMUS; SKIN NEOPLASMS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84939466537     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.05.029     Document Type: Article

References (21)

1. F.O. Zwald, and M. Brown Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients J Am Acad Dermatol 65 2 2011 253 261
2. C.A. Harwood, C.M. Proby, J.M. McGregor, M.T. Sheaff, I.M. Leigh, and R. Cerio Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series J Am Acad Dermatol 54 2 2006 290 300
3. J.C. Martinez, C.C. Otley, T. Stasko, et al. Transplant-Skin Cancer Collaborative Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study Arch Dermatol 139 3 2003 301 306
4. A. Ingvar, K.E. Smedby, B. Lindelöf, and et al. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma Nephrol Dial Transplant 25 8 2010 2764 2771
5. A. Jensen, C. Svaerke, D. Farkas, and et al. Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark Acta Derm Venereol 90 5 2010 474 479
6. H. Ramsay, A. Fryer, C. Hawley, and et al. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia J Am Acad Dermatol 49 3 2003 397 406
7. P. Jensen, S. Hansen, B. Møller, and et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens J Am Acad Dermatol 40 2 Pt 1 1999 177 186
8. J. Campistol, J. Eris, R. Oberbauer, and et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation J Am Soc Nephrol 17 2 2006 581 589
9. K.G. Leblanc Jr., M.P. Hughes, and D.J. Sheehan The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients Dermatol Surg 37 6 2011 744 749
10. P. Amornphimoltham, V. Patel, A. Sodhi, and et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck Cancer Res 65 2005 9953 9961
11. J.M. Hoogendijk-van den Akker, P.N. Harden, A.J. Hoitsma, and et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus J Clin Oncol 31 10 2013 1317 1323
12. R.P. Carroll, J. Hester, K.J. Wood, and P.N. Harden Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype Nephrol Dial Transplant 28 2 2013 462 465
13. S. Euvrard, E. Morelon, L. Rostaing, et al. TUMORAPA Study Group Sirolimus and secondary skin-cancer prevention in kidney transplantation N Engl J Med 367 4 2012 329 339
14. S.B. Campbell, R. Walker, S.S. Tai, Q. Jiang, and G.R. Russ Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer Am J Transplant 12 5 2012 1146 1156
15. J. Alberú, M.D. Pascoe, J.M. Campistol, et al. Sirolimus CONVERT Trial Study Group Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial Transplantation 92 3 2011 303 310
16. R. Salgo, J. Gossmann, H. Schofer, and et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial Am J Transplant 10 2010 1385 1393
17. G.A. Knoll, M.B. Kokolo, R. Mallick, and et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data BMJ 349 2014 g6679
18. M. Alter, I. Satzger, H. Schrem, A. Kaltenborn, A. Kapp, and R. Gutzmer Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients J Dtsch Dermatol Ges 12 6 2014 480 488
19. Gordon N. Similarity of the adult Kaiser Permanente membership in northern California to the insured and general population in northern California: statistics from the 2009 California health interview survey. Internal Division of Research report. Oakland (CA): Kaiser Permanente Division of Research; 2012. Available from: URL: http://www.dor.kaiser.org/external/chis-non-kp-2009/. Accessed July 7, 2014.
20. A.S. Go, W.Y. Lee, J. Yang, J.C. Lo, and J.H. Gurwitz Statin therapy and risks for death and hospitalization in chronic heart failure JAMA 296 2006 2105 2111
21. H.H. Moffet, N. Adler, D. Schillinger, and et al. Cohort profile: the diabetes study of northern California (DISTANCE)-objectives and design of a survey follow-up study of social health disparities in a managed care population Int J Epidemiol 38 1 2009 38 47